In the CLL cohort, tumor-exclusive peptides were identified with a frequency of up to 30% (figure 4b and d), with HLA-A*02:01 representing the allotype for 17 of the 20 most abundant peptides (online supplemental figure 10b). This evidence concerns the gene HLA-A and B-cell chronic lymphocytic leukemia.